Recent Updates
Recently added Catalysts

cbdMD, Inc.

YCBDFDA catalysts, PDUFA dates & pipeline intelligence
$0.36
▲ +0 · +0.28%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full YCBD financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.4752W HIGH $2.56
Volume
151.18 K
Value Traded
53.38 K
Short % Float
4.79%
Days to Cover
7.4
-2.45%Week
-9.88%1 Month
-17.29%3 Month
+40.26%6 Month
-99.93%5 Year
-99.96%All Time

Cash Data

Unlock YCBD cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
4.08 M
EPS (TTM)
-0.41
P/E Ratio
-
Ent. Value
5.77 M
Total Shares
10.50 M
Float Shares
10.07 M
Insiders
10.13%
Institutions
6.97%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every YCBD catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

YCBD Catalyst Timeline

Dated clinical, regulatory and corporate events for cbdMD, Inc.

Unlock the full YCBD catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How YCBD actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all YCBD historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

cbdMD, Inc. is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every YCBD program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every YCBD trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock YCBD insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Crosnoe Clark R.10% OwnerSell -461,725 361,400 held$2.31 12/17/2025
Unlock the full YCBD insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in YCBD for Q3 2026.
Unlock every fund holding YCBD
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in YCBD
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see YCBD ownership
Insider and institutional ownership, quarter by quarter.

YCBD Short Interest

Shares sold short, counted twice a month.

4.79%
Short % of Float
of tradable shares sold short
482.6K
Shares Sold Short
-11.6% vs prior count
7.4 High
Days to Cover
trading days of normal volume to buy every short share back
65.3K
Avg Daily Volume
the average used for days to cover
Unlock YCBD short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock YCBD option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live YCBD option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock YCBD options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How YCBD ranks across every disease it competes in

Competitive Position is a premium feature
See how YCBD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

YCBD News

YCBD
Nov 18, 2026
YCBDGeneral
▲ +0.3%today

cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue

cbdMD supports the Bipartisan Hemp Guardrails Act, introduced by Senators Sheehy and Klobuchar, to establish federal standards for hemp products. The legislation averts a December 11 ban that would remove lawful items from the market. cbdMD CEO Ronan Kennedy stated the bill protects consumers while preserving 350,000 American jobs. The company also highlighted its diversified portfolio, including Twinlab, to mitigate regulatory risks.

Read more →
YCBD
Nov 2, 2026
YCBDGeneral

cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness

cbdMD has successfully acquired the operating assets of Twinlab, including its well-known brands like Reserveage and Metabolife. This acquisition aims to diversify cbdMD's offerings beyond hemp products and enhance its market presence. CEO Ronan Kennedy emphasized the significance of this deal for the company's growth and innovation strategy.

Read more →
YCBD
Sep 24, 2026
YCBDGeneral

Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation

Reserveage has launched Longev+, a new supplement available exclusively at The Vitamin Shoppe. This product combines essential amino acids, HMB, creatine, and resveratrol to support muscle health and performance. The launch reflects consumer demand for simpler wellness routines and flavorful supplements. It also aligns with cbdMD's proposed acquisition of Twinlab brands.

Read more →
YCBD
Sep 2, 2026
YCBDGeneral

cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness

cbdMD has signed a definitive agreement to acquire Twinlab Brands, which includes well-known names like Twinlab, Reserveage, and Metabolife. This acquisition is anticipated to boost cbdMD's revenue to around $30 million and diversify its product offerings beyond hemp-derived products. The deal is subject to court approval and aims to stabilize Twinlab's brands while enhancing cbdMD's market presence.

Read more →
YCBD
Aug 13, 2026
YCBDGeneral
▼ -12.3%on this news

cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

cbdMD reported a 20% increase in revenue for Q3 2026, driven by strong wholesale sales and contributions from Bluebird Botanicals. The company is also seeing positive momentum with its Oasis beverage brand. However, one-time costs related to mergers and acquisitions have impacted profitability. The regulatory landscape is improving, providing a favorable outlook for future growth.

Read more →
YCBD
Aug 10, 2026
YCBDConferences/Events

cbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results

cbdMD, Inc. will host a conference call on August 13, 2026, at 4:20 p.m. ET to discuss its third quarter financial results for the period ending June 30, 2026. The call will provide insights into the company's business progress and financial performance. Interested parties can join via a dedicated phone line or through a webcast.

Read more →
YCBD
Aug 3, 2026
YCBDGeneral
▲ +5%on this news

cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products

cbdMD, Inc. has welcomed a proposed Senate spending bill that aims to delay federal restrictions on hemp products, preserving access to full-spectrum CBD. The bill, released on August 2, is seen as a significant victory for the hemp industry. However, it still requires approval from the House and the President before becoming law.

Read more →
YCBD
Jul 24, 2026
YCBDGeneral

cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access

cbdMD, Inc. has announced its support for the bipartisan Lawful Hemp Protection Act, which aims to create a federal regulatory framework for hemp-derived products. This legislation is crucial as the federal definition of hemp is set to narrow in November 2026, potentially removing many lawful CBD products from the market. The Act seeks to ensure consumer access while implementing safety standards and oversight.

Read more →
YCBD
Jul 14, 2026
YCBDGeneral

cbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina

cbdMD, Inc. has announced the launch of its Oasis line of hemp-derived beverages in South Carolina through a partnership with Mexcor. The rollout includes the new zero-proof Mixer, designed for cocktails, now available at various liquor retailers. This strategic move aims to increase brand visibility and accessibility for consumers in familiar shopping environments.

Read more →
YCBD
Jul 9, 2026
YCBDGeneral
▲ +8%on this newsshared move

cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation

cbdMD's Bluebird Botanicals has partnered with Denver Audubon to support bird conservation in Colorado. This collaboration emphasizes Bluebird's commitment to environmental values and responsible growth. As part of the initiative, Bluebird will contribute 1% of its product sales to support conservation and education efforts. The partnership aims to strengthen Bluebird's identity while promoting community engagement in wildlife stewardship.

Read more →
YCBD
Jul 7, 2026
YCBDFDA Updates

cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination

cbdMD has announced the completion of a self-affirmed GRAS determination, allowing for the safe daily consumption of up to 200 mg of its broad spectrum CBD products. This conclusion is based on years of rigorous safety research and peer-reviewed studies. The determination is expected to enhance consumer confidence and support the company's product positioning in the growing CBD market.

Read more →
YCBD
Jul 1, 2026
YCBDGeneral

Oasis Launches Hemp-Derived Mixer

cbdMD, Inc. has launched Oasis Mixer, a new hemp-derived THC spirit that is translucent and oil-free, addressing consumer demand for cleaner beverage options. The product is available in Citrus and Unflavored varieties, each containing 10mg of THC per serving. Initial demand has exceeded supply, indicating strong market interest. Oasis Mixer is compliant with child-resistant packaging regulations in Texas.

Read more →
YCBD
Jun 25, 2026
YCBDGeneral

cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products

cbdMD, Inc. has welcomed the White House's call for fair treatment of hemp-derived products, urging Congress to revise federal regulations. The Administration's push aims to preserve access to full-spectrum CBD while ensuring consumer safety. cbdMD believes it is well-positioned in the evolving cannabinoid market, advocating for responsible regulation and quality products.

Read more →
YCBD
Jun 16, 2026
YCBDGeneral

cbdMD Appoints Wade Brown Chief Marketing Officer

cbdMD, Inc. has appointed Wade Brown as Chief Marketing Officer to lead its multi-brand expansion. Brown, who joined the company in March 2025, has played a crucial role in stabilizing the brand portfolio and supporting the acquisition of Bluebird Botanicals. The company reported a 19% year-over-year revenue growth, indicating strong momentum in its core brands. Brown's extensive experience in consumer marketing is expected to drive cbdMD's next phase of growth.

Read more →
YCBD
May 14, 2026
YCBDGeneral
▼ -5.3%on this news

cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum

cbdMD, Inc. reported a 19% year-over-year revenue growth for Q2 2026, driven by its core business and the integration of Bluebird Botanicals. The company is positioned for continued growth with the activation of the Medicare BEI pathway for hemp-derived CBD products. Despite increased operational losses, cbdMD remains optimistic about future opportunities in the evolving regulatory landscape.

Read more →
YCBD
May 12, 2026
YCBDConferences/Events

cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results

cbdMD, Inc. will host a conference call on May 14, 2026, at 4:20 p.m. ET to discuss its second quarter financial results for the period ending March 31, 2026. The call will provide insights into the company's business progress and financial performance. Interested parties can join via a dedicated phone line or through a webcast.

Read more →
YCBD
Apr 1, 2026
YCBDFDA Updates

cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare

cbdMD launched a clinical healthcare channel to supply hemp-derived CBD to Medicare patients under new CMS guidance. The Substance Access Beneficiary Engagement Incentive allows participating organizations to furnish these products. The company cites unique OECD-standard toxicology and human clinical trial data as key differentiators for physician adoption.

Read more →
YCBD
Feb 17, 2026
YCBDGeneral
▲ +10.7%on this news· ran to +35% by day 3

cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

cbdMD, Inc. reported a 12% sequential revenue growth for Q1 of fiscal 2026, reflecting stabilization in its core business. The company also announced the strategic acquisition of Bluebird Botanicals, which is expected to enhance its revenue and operational efficiencies. Despite these positives, net sales saw a slight decrease compared to the previous year.

Read more →
YCBD
Feb 12, 2026
YCBDConferences/Events
▼ -9.1%on this newsshared move

cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

cbdMD, Inc. will host a conference call on February 17, 2026, at 4:20 p.m. ET to discuss its first quarter financial results for the period ending December 31, 2025. The call aims to provide updates on the company's business progress and financial performance. Interested parties can join via phone or webcast.

Read more →
YCBD
Feb 2, 2026
YCBDGeneral
▼ -16.4%on this news

cbdMD's Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum

cbdMD announced a distribution expansion for its Herbal Oasis THC-infused seltzer into Louisiana through a partnership with Morales Beverage Group. This move follows strong sales in Texas and aims to enhance the brand's presence in the Gulf South. The company expects to start shipping products by late February.

Read more →

About cbdMD, Inc.

Charlotte, NC 42 employees cbdmd.com
Headquarters8845 RED OAK BOULEVARD, CHARLOTTE, NC, 28217
BIOPHARMAWATCH ELITE
Trade the next YCBD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime